论文部分内容阅读
业绩小幅低于预期瑞普生物前三季度实现营业收入5.36亿元,同比增长14.4%;归属母公司净利润9,663万元,同比增长5.5%;扣非后净利润同比增长约为17%,略低于预期。三季度公司营业收入同比增长14.1%,净利润同比增长6.2%至2,656万元。猪圆环疫苗表现亮眼:受益于重点新品的陆续上市及养殖业景气复苏,市场疫苗业务三季度实现收入约9,000万元,同比增长64%,增速较上半年大
Results slightly lower than expected Rip’s biological first three quarters operating income 536 million yuan, an increase of 14.4%; net profit attributable to parent company 9666300 yuan, an increase of 5.5%; non-net profit after deducting non-profit increased by about 17% Lower than expected. In the third quarter, the company’s operating income increased by 14.1% from the same period of last year, and net profit increased by 6.2% to RMB26.56 million. Pig ring vaccine performance dazzling: to benefit from the successive listing of key new products and aquaculture boom recovery, the market of vaccine business in the third quarter to achieve revenue of about 90 million yuan, an increase of 64% growth rate higher than the first half